HomeContact Details:
t.d.warner@qmul.ac.uk
Tim Warner graduated in pharmacology in 1986 from King’s College London. He then moved to the newly established William Harvey Research Institute to pursue his PhD studies under the supervision of Prof. Sir John Vane during which time he was awarded the Premier Prix Annuel de Recherche en Phlébologie. In 1989 he completed his PhD and went to pursue his post-doctoral studies with Ferid Murad at Northwestern University and Abbott Laboratories, Chicago, USA. He returned to the William Harvey Research Institute in 1992, being awarded a British Heart Foundation lectureship in 1995. He was promoted Reader in Pharmacology in 1999 and awarded a personal chair in Vascular Inflammation in 2000, at which time he was the recipient of the British Pharmacology Society’s Novartis Prize. He is a Fellow of the British Pharmacological Society as well as being a member of the American Heart Association, American Society for Pharmacology and Experimental Therapeutics, British Society for Cardiovascular Research, International Society for Hypertension Research and the International Society on Thrombosis and Haemostasis. Tim Warner has been listed by the Institute for Scientific Information among the top 0.5% of cited pharmacologists.
Current research interests
Prof. Warner’s main focus of current research is the roles of different enzyme pathways in the formation of prostaglandin I2 and thromboxane A2 in blood vessels and blood cells, and measures of platelet reactivity. This is supported by programme grant funding from the Wellcome Trust to Prof. Warner in collaboration with Prof. Jane Mitchell at Imperial College. Locally, researches into platelet reactivity are being pursued in collaboration with clinical colleagues in the Haematology Department, the Ernest Cooke Vascular & Microvascular Unit, and the Cardiac Directorate of the Barts & the London NHS Trust. Heart Research UK fund a further collaborative project with Dr Paul Harrison at the Oxford Haemophilia and Thrombosis Centre into the interactions between platelets and von Willebrand Factor. The British Heart Foundation are currently funding research into the platelet and vascular effects of 12HETE produced by activated platelets. Prof. Warner has also received funding from AstraZeneca to pursue investigations into interactions between different pathways of platelet activation.
Available projects
Prof. Warner is particularly looking for researchers interested in further development of projects into therapeutic interventions to regulate platelet reactivity in at risk individuals. These will exploit growing collaborations between Prof. Warner’s group and clinical teams and could suit both basic science and clinical researchers.
Key publications
-
Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Warner TD, Nylander S, Whatling C. Br J Clin Pharmacol. 2011 Feb 15. doi: 10.1111/j.1365-2125.2011.03943.x. [Epub ahead of print].
-
In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. JThromb Haemost. 2011 Mar;9(3):552-61. doi: 10.1111/j.1538-7836.2010.04160.x.
-
Role of shear stress in endothelial cell morphology and expression of cyclooxygenase isoforms. Potter CM, Lundberg MH, Harrington LS, Warboys CM, Warner TD, Berson RE, Moshkov AV, Gorelik J, Weinberg PD, Mitchell JA. Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):384-91. Epub 2010 Dec 2.
-
Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists? Warner TD, Armstrong PC, Curzen NP, Mitchell JA. Heart. 2010 Nov;96(21):1693-4.
-
Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD. J Thromb Haemost. 2010 Mar;8(3):613-5. Epub 2009 Dec 3. No abstract available.
-
.Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Armstrong PC, Dhanji AR, Truss NJ, Zain ZN, Tucker AT, Mitchell JA, Warner TD. Thromb Haemost. 2009 Oct;102(4):772-8.
-
PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha--brief report. Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA.Arterioscler Thromb Vasc Biol. 2009 Nov;29(11):1871-3. Epub 2009 Aug 20.
-
Heparin but not citrate anticoagulation of blood preserves platelet function for prolonged periods. Truss NJ, Armstrong PC, Liverani E, Vojnovic I, Warner TD.J Thromb Haemost. 2009 Nov;7(11):1897-905. Epub 2009 Aug 19.
-
Rapid and accurate method for the von Willebrand factor ristocetin cofactor assay using 96-well microtiter plates. Truss NJ, Beavis J, MacCallum PK, Harrison P, Warner TD. J Thromb Haemost. 2009 Jul;7(7):1226-8. Epub 2009 Apr 30. No abstract available.
-
Antiplatelet actions of statins and fibrates are mediated by PPARs. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, Mitchell JA, Warner TD. Arterioscler Thromb Vasc Biol. 2009 May;29(5):706-11. Epub 2009 Jan 15.
-
Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. Armstrong PC, Truss NJ, Ali FY, Dhanji AA, Vojnovic I, Zain ZN, Bishop-Bailey D, Paul-Clark MJ, Tucker AT, Mitchell JA, Warner TD. J Thromb Haemost. 2008 Nov;6(11):1933-43. Epub 2008 Jan 11.
- COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Warner TD, Mitchell JA. Lancet. 2008 Jan 19;371(9608):270-3. Review. No abstract available.
Search for more publications by Tim Warner
